Developer docs
API playgroundTry for free, no card

Search company profiles

Altavant Sciences

Full company profile

uuid002hy7u

Namestring
Altavant Sciences
Websiteurl
altavant.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Altavant Sciences is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Cary, North Carolina. The company focuses on developing treatments for interstitial lung disease, an area where the addressable market is projected to reach $3.09 billion by 2030 at an 8.4% CAGR. Altavant builds its pipeline through both internal development and acquisitions, most notably acquiring Onspira Therapeutics in January 2020 for an undisclosed amount to bring in respiratory and rare-disease assets.

The company operates with a lean team of 11-50 employees under a senior leadership structure typical of clinical-stage biotechs: Bill Symonds serves as CEO, Howard Lazarus as Chief Medical Officer, Lyn Baranowski as Chief Operating Officer, and Beth Anne Lang as Senior Vice President of Global Regulatory Affairs. This composition emphasizes clinical development execution and regulatory navigation rather than commercial-scale functions, consistent with a pre-commercial stage of development. Altavant is privately held, has not disclosed funding rounds in the provided data, and generates no commercial product revenue based on available information. Its business model is therefore dependent on capital markets and/or strategic partnerships to fund continued clinical advancement of its ILD pipeline.

Short descriptiontext

Altavant Sciences is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Cary, NC, developing treatments for interstitial lung disease through in-licensed and acquired pipeline assets (including Onspira Therapeutics).

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCary, United States
HQ citystring
Cary
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
clinical-stage biopharmaceutical, interstitial lung disease therapeutics, rare disease drug development, respiratory disease pipeline, small-molecule therapeutics
Industry2 codes
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAFAMAL
Clinical Research & Trial Central Laboratories
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals / Drug Development
Social media profiles1 record
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Altavant Sciences is a clinical-stage biopharmaceutical company developing therapeutics for interstitial lung disease (ILD) and rare respiratory conditions. The company expanded its pipeline through the acquisition of Onspira Therapeutics on 2020-01-08, bringing in complementary drug development programs. It operates as a development-focused subsidiary within the Sumitomo Pharma group, targeting an ILD market projected to reach $3.09 billion by 2030.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Clinical-stage ILD therapeutic pipeline
CategoryBiopharmaceutical Pipeline
Description

Clinical-stage biopharmaceutical development programs targeting interstitial lung disease and rare respiratory conditions, acquired through the Onspira Therapeutics transaction and advanced under the Sumitomo Pharma group. Intended for onward commercialization or partnership with larger biopharma organizations.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Prometheus Biosciences
TypeOthers
Description

Prometheus Biosciences was acquired by Merck, mentioned in market context as a key development in the interstitial lung disease space to enhance pipeline capabilities.

openpr.com
Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Biopharma with late-stage programs in IPF/ILD (pamrevlumab) and other fibrotic diseases; directly comparable therapeutic focus and clinical stage.

TypeDirect peer
Description

Clinical-stage biopharma developing therapies for idiopathic pulmonary fibrosis and other ILDs; directly comparable in indication, stage, and therapeutic modality.

TypeEmerging player
Description

Clinical-stage biopharma developing therapeutics for refractory chronic cough and related respiratory conditions; comparable as a small respiratory-focused clinical developer.

4Horizon Therapeutics (Amgen)
TypeBroad incumbent
Description

Specialty/rare disease biopharma with respiratory inflammation programs (e.g., Actimmune for IPF); broader portfolio but overlapping in rare respiratory disease development.

TypeEmerging player
Description

Clinical-stage biopharma "Vant" platform developing multiple therapeutic candidates including respiratory assets; comparable as a small-focused clinical-stage entity with similar development philosophy.

TypeOthers
Description

U.S. subsidiary of Sumitomo Pharma with rare disease and respiratory programs referenced in the company data; relevant as a strategic/pharma ecosystem participant in the ILD space.

7Boehringer Ingelheim
TypeBroad incumbent
Description

Established large-pharma with the approved ILD therapy nintedanib (Ofev); broader respiratory portfolio but directly defines the ILD competitive landscape Altavant must navigate.

TypeDirect peer
Description

Specialty biopharma with pulmonary hypertension and ILD-relevant programs (tyvaso DPI for PH-ILD); comparable in rare respiratory disease focus and commercialization model.

TypeDirect peer
Description

Developed ziritaxestat and other IPF/ILD candidates through clinical trials; directly comparable in ILD drug development activity and pipeline focus.

10Blade Therapeutics
TypeEmerging player
Description

Clinical-stage company developing antifibrotic therapies for IPF and other fibrotic diseases; comparable as a smaller, focused ILD/fibrosis developer.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Altavant Sciences

Biopharmaceuticals / Drug Developmentaltavant.com

Altavant Sciences is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Cary, NC, developing treatments for interstitial lung disease through in-licensed and acquired pipeline assets (including Onspira Therapeutics).

What Altavant Sciences does

Altavant Sciences is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Cary, North Carolina. The company focuses on developing treatments for interstitial lung disease, an area where the addressable market is projected to reach $3.09 billion by 2030 at an 8.4% CAGR. Altavant builds its pipeline through both internal development and acquisitions, most notably acquiring Onspira Therapeutics in January 2020 for an undisclosed amount to bring in respiratory and rare-disease assets.

The company operates with a lean team of 11-50 employees under a senior leadership structure typical of clinical-stage biotechs: Bill Symonds serves as CEO, Howard Lazarus as Chief Medical Officer, Lyn Baranowski as Chief Operating Officer, and Beth Anne Lang as Senior Vice President of Global Regulatory Affairs. This composition emphasizes clinical development execution and regulatory navigation rather than commercial-scale functions, consistent with a pre-commercial stage of development. Altavant is privately held, has not disclosed funding rounds in the provided data, and generates no commercial product revenue based on available information. Its business model is therefore dependent on capital markets and/or strategic partnerships to fund continued clinical advancement of its ILD pipeline.

Altavant Sciences firmographics

Firmographics
Name
Altavant Sciences
Website
https://altavant.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Altavant Sciences is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Cary, NC, developing treatments for interstitial lung disease through in-licensed and acquired pipeline assets (including Onspira Therapeutics).
Ownership category
akta.pro rank

Altavant Sciences industry classification

Industry
Product category
Biopharmaceuticals / Drug Development
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAFAMAL
Clinical Research & Trial Central Laboratories

Keywords

  • Clinical-stage biopharmaceutical
  • Interstitial lung disease therapeutics
  • Rare disease drug development
  • Respiratory disease pipeline
  • Small-molecule therapeutics

Where Altavant Sciences is headquartered

Location

Headquarters

HQ city
Cary
HQ country
United States
HQ region
North America

Markets served

Altavant Sciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Altavant Sciences product offering

Product offering

Core offering

Altavant Sciences is a clinical-stage biopharmaceutical company developing therapeutics for interstitial lung disease (ILD) and rare respiratory conditions. The company expanded its pipeline through the acquisition of Onspira Therapeutics on 2020-01-08, bringing in complementary drug development programs. It operates as a development-focused subsidiary within the Sumitomo Pharma group, targeting an ILD market projected to reach $3.09 billion by 2030.

Differentiator

Problem solved

Functional benefit

Products and services

  • Clinical-stage ILD therapeutic pipeline Clinical-stage biopharmaceutical development programs targeting interstitial lung disease and rare respiratory conditions, acquired through the Onspira Therapeutics transaction and advanced under the Sumitomo Pharma group. Intended for onward commercialization or partnership with larger biopharma organizations.

Companies that use Altavant Sciences

Customer profile

Ideal customer profiles1 record

Altavant Sciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Altavant Sciences partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Prometheus BiosciencesOthersPrometheus Biosciences was acquired by Merck, mentioned in market context as a key development in the interstitial lung disease space to enhance pipeline capabilities.

Scale indicators1 record

Recent moves3 records

Expansion highlights3 records

Altavant Sciences competitors and assessment

Company assessment

Direct peers

  • FibroGen: Biopharma with late-stage programs in IPF/ILD (pamrevlumab) and other fibrotic diseases; directly comparable therapeutic focus and clinical stage.
  • Pliant Therapeutics: Clinical-stage biopharma developing therapies for idiopathic pulmonary fibrosis and other ILDs; directly comparable in indication, stage, and therapeutic modality.
  • United Therapeutics: Specialty biopharma with pulmonary hypertension and ILD-relevant programs (tyvaso DPI for PH-ILD); comparable in rare respiratory disease focus and commercialization model.
  • Galapagos NV: Developed ziritaxestat and other IPF/ILD candidates through clinical trials; directly comparable in ILD drug development activity and pipeline focus.

Emerging players

  • Bellus Health: Clinical-stage biopharma developing therapeutics for refractory chronic cough and related respiratory conditions; comparable as a small respiratory-focused clinical developer.
  • Roivant Sciences: Clinical-stage biopharma "Vant" platform developing multiple therapeutic candidates including respiratory assets; comparable as a small-focused clinical-stage entity with similar development philosophy.
  • Blade Therapeutics: Clinical-stage company developing antifibrotic therapies for IPF and other fibrotic diseases; comparable as a smaller, focused ILD/fibrosis developer.

Broad incumbents

  • Horizon Therapeutics (Amgen): Specialty/rare disease biopharma with respiratory inflammation programs (e.g., Actimmune for IPF); broader portfolio but overlapping in rare respiratory disease development.
  • Boehringer Ingelheim: Established large-pharma with the approved ILD therapy nintedanib (Ofev); broader respiratory portfolio but directly defines the ILD competitive landscape Altavant must navigate.

Others

  • Sumitomo Pharma America: U.S. subsidiary of Sumitomo Pharma with rare disease and respiratory programs referenced in the company data; relevant as a strategic/pharma ecosystem participant in the ILD space.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights4 records

Customer concentration

Altavant Sciences social profiles

Digital presence

Altavant Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Altavant Sciences leadership team

Management profile

Number of profiles

Profiles4 records

Altavant Sciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Altavant Sciences M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Altavant Sciences

What does Altavant Sciences do?

Altavant Sciences is a clinical-stage biopharmaceutical company developing therapeutics for interstitial lung disease (ILD) and rare respiratory conditions. The company expanded its pipeline through the acquisition of Onspira Therapeutics on 2020-01-08, bringing in complementary drug development programs. It operates as a development-focused subsidiary within the Sumitomo Pharma group, targeting an ILD market projected to reach $3.09 billion by 2030.

Is Altavant Sciences a public or private company?

Altavant Sciences is a private company. It is classified as corporate owned and is currently operating.

When was Altavant Sciences founded?

Altavant Sciences was founded in 2018. It employs 11 to 50 people.

Where is Altavant Sciences based?

Altavant Sciences is headquartered in Cary, United States, in the North America region.

Who are Altavant Sciences's main competitors?

Direct peers on record are FibroGen, Pliant Therapeutics, United Therapeutics and Galapagos NV. Emerging players are Bellus Health, Roivant Sciences and Blade Therapeutics. Broad incumbents are Horizon Therapeutics (Amgen) and Boehringer Ingelheim. Sumitomo Pharma America is listed as an others.

Does Altavant Sciences have an API?

No public API is recorded for Altavant Sciences.

What industry is Altavant Sciences in?

Altavant Sciences's product category is Biopharmaceuticals / Drug Development. Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals, with a secondary code of HLAFAMAL, Clinical Research & Trial Central Laboratories. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American City Business JournalsEnzyvant, Altavant merger creates Cary company aimed at rare diseasesTwo biopharmaceutical firms merged to create a new company based in Cary, North Carolina, with plans for a new manufacturing facility. The company's headquarters are on CentreGreen Way, and the facility is well underway.PR NewswireALTAVANT SCIENCES PRESENTS DATA SHOWING POTENTIAL FOR COMBINATION OF RODATRISTAT ETHYL AND AMBRISENTAN IN MODEL OF PULMONARY ARTERIAL HYPERTENSIONAltavant Sciences announced preclinical study results demonstrating that rodatristat ethyl, both as a monotherapy and in combination with ambrisentan, reversed vascular occlusions in an animal model of pulmonary arterial hypertension. The company will present these findings at the American Thoracic Society 2022 conference in San Francisco.PR NewswireALTAVANT SCIENCES PRESENTED DATA AT ISHLT SHOWING POTENCY AND DISTRIBUTION OF BRONCHIOLITIS OBLITERANS CANDIDATE, ALTA-2530Altavant Sciences presented preclinical data at the International Society for Heart & Lung Transplantation annual meeting in Boston, demonstrating that its drug candidate ALTA-2530 achieved effective distribution to distal lung regions and exhibited significantly greater binding affinity for the IL-1 type 1 receptor compared to endogenous ligands. The inhaled interleukin-1 receptor antagonist also showed potent inhibition of IL-1β stimulated IL-6 expression, supporting its potential as a treatment for bronchiolitis obliterans syndrome, a life-threatening form of chronic lung allograft dysfunction with no currently approved therapies.PR NewswireALTAVANT SCIENCES TO PRESENT DATA AT ISHLT SHOWING POTENCY AND DISTRIBUTION OF BRONCHIOLITIS OBLITERANS CANDIDATE, ALTA-2530Altavant Sciences announced it will present preclinical data for its BOS (bronchiolitis obliterans syndrome) drug candidate ALTA-2530 at the International Society for Heart & Lung Transplantation annual meeting in Boston, April 27-30, 2022. The company will share two presentations: one on patient insights gathered from an advisory meeting regarding chronic lung allograft dysfunction, and another on in vivo and in vitro preclinical study results demonstrating ALTA-2530's lung distribution and IL-1 receptor blocking potency. ALTA-2530 is an inhaled interleukin-1 receptor antagonist currently in preclinical development for BOS, a life-threatening condition with no approved therapies.PR NewswireAltavant Sciences Highlights Ongoing Phase 2b ELEVATE 2 Study of Rodatristat Ethyl in Patients with Pulmonary Arterial Hypertension at European Respiratory Society Annual CongressAltavant Sciences presented an e-poster at the European Respiratory Society annual congress outlining the protocol and design of the ongoing Phase 2b ELEVATE 2 study of rodatristat ethyl in patients with pulmonary arterial hypertension. The novel molecule, which lowers peripheral serotonin synthesis via tryptophan hydroxylase inhibition, demonstrated in animal models a reduction in PAH-like remodeling and mean pulmonary arterial pressure superior to ambrisentan plus tadalafil, with dose-range finding studies showing up to ~60% reduction in peripheral serotonin levels.PR NewswireAltavant Sciences Reports Rodatristat Ethyl PK/PD Analysis at ATS Supporting Doses Selected for Phase 2b ELEVATE 2 StudyAltavant Sciences presented pharmacokinetic and pharmacodynamic findings for its lead candidate rodatristat ethyl at the American Thoracic Society meeting, announcing that doses of 300mg and 600mg twice daily were identified through 10,000 simulations as optimal for achieving a 40% reduction in serotonin biosynthesis targeted for pulmonary arterial hypertension treatment. The Phase 2b ELEVATE 2 study is now enrolling patients at sites in the US with expansion to the EU and Canada later this year. CEO Bill Symonds stated the company is excited to begin enrolling patients following the dose selection milestone.PR NewswireAltavant Sciences Provides Update on Clinical Plan for PAH Candidate, Rodatristat Ethyl, at Upcoming American Thoracic Society Annual MeetingAltavant Sciences, a clinical-stage biopharmaceutical company, will present clinical development updates for its lead PAH candidate rodatristat ethyl at the American Thoracic Society annual meeting in May 2021. The company is conducting a randomized, double-blind Phase 2b study (ELEVATE 2) enrolling up to 90 adults with pulmonary arterial hypertension across sites in the US, Canada and Europe. The study evaluates two dose levels of rodatristat ethyl against placebo over 24 weeks, with findings based on favorable pharmacokinetic and pharmacodynamic data.GlobeNewswireAltavant Sciences Advances Rodatristat Ethyl into Phase 2b Clinical Trial for Pulmonary Arterial HypertensionAltavant Sciences initiated its ELEVATE 2 Phase 2b trial of rodatristat ethyl for pulmonary arterial hypertension. The dose-ranging, randomized, double-blind, placebo-controlled study will enroll about 90 adults with WHO Group 1 PAH. Efficacy will be measured by percent change in pulmonary vascular resistance.GlobeNewswireCary, N.C. and Basel, Switzerland s Finds Nebulized ALTA-2530 Retains Potency and Reaches Target Lung Tissues, Supporting Continued Investigation for Treatment of BOSAltavant Sciences presented in vitro and in vivo data for nebulized ALTA-2530, a recombinant human IL-1 receptor antagonist, at the ISHLT virtual poster session. The drug reached lung epithelial lining fluid at concentrations ~2,500-fold higher than serum and retained full potency after nebulization, supporting further investigation for bronchiolitis obliterans syndrome.